Merck (MRK) Net Cash Flow (2009 - 2026)
Merck (MRK) posted quarterly Net Cash Flow of -$9.3 billion for Q1 2026, down 95.55% year-over-year from -$208.4 billion in Q1 2025, and down 158.09% quarter-over-quarter from -$3.6 billion in Q4 2025.
Merck (MRK) Net Cash Flow (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Net Cash Flow for 18 consecutive years, with -$9.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 95.55% year-over-year to -$9.3 billion; the TTM figure through Mar 2026 stood at -$3.7 billion (down 221.63% YoY), while the FY2025 annual figure was $809.0 million, down 87.93% from the prior year.
- Net Cash Flow retreated to -$9.3 billion in Q1 2026 per MRK's latest filing, from -$3.6 billion in the prior quarter.
- Across five years, Net Cash Flow topped out at $10.2 billion in Q3 2025 and bottomed at -$9.3 billion in Q1 2026.
- Historically, Net Cash Flow has averaged -$154.9 million across 5 years, with a median of -$1.0 billion in 2024.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 712.35% — and 2024, when it soared 245.29%.
- Merck's Net Cash Flow stood at $1.1 billion in 2022, then tumbled by 272.52% to -$1.9 billion in 2023, then jumped by 48.46% to -$1.0 billion in 2024, then tumbled by 258.23% to -$3.6 billion in 2025, then tumbled by 158.09% to -$9.3 billion in 2026.
- Business Quant data shows MRK's Net Cash Flow at -$9.3 billion in Q1 2026, -$3.6 billion in Q4 2025, and $10.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Bn |
| Jun 30, 2026 | 1.53 Bn |
| Mar 31, 2026 | -9.27 Bn |
| Mar 31, 2026 | -9.27 Bn |
| Dec 31, 2025 | -3.59 Bn |
| Dec 31, 2025 | -3.59 Bn |
| Sep 30, 2025 | 10.18 Bn |
| Sep 30, 2025 | 10.18 Bn |
| Jun 30, 2025 | -1.03 Bn |
| Jun 30, 2025 | -1.03 Bn |
| Mar 31, 2025 | -4.74 Bn |
| Mar 31, 2025 | -4.74 Bn |
| Dec 31, 2024 | -1.00 Bn |
| Dec 31, 2024 | -1.00 Bn |
| Sep 30, 2024 | 3.02 Bn |
| Sep 30, 2024 | 3.02 Bn |
| Jun 30, 2024 | 5.78 Bn |
| Jun 30, 2024 | 5.78 Bn |
| Mar 31, 2024 | -1.10 Bn |
| Mar 31, 2024 | -1.10 Bn |